US Edition
mRNA vaccine hope for pancreatic cancer, fertility facts, smarter skin and hair care
Eight of 16 patients mounted an immune response, and seven responders were alive six years later, researchers said.
- A personalized mRNA vaccine from BioNTech showed promise in a pancreatic cancer trial, where 8 of 16 patients mounted a successful immune response. Seven of those eight remained alive six years after the trial began.
- Pancreatic cancer remains among the most lethal of all cancers, claiming the lives of 88 percent of those diagnosed. In this study, participants underwent surgery to remove tumors before receiving the vaccine over nine weeks.
- Tumor samples were sent to BioNTech, which created a personalized vaccine for each individual patient. This approach addresses the genetic complexity of tumors, which often allows them to evade standard treatments.
- Experts emphasize caution regarding these encouraging results, as the trial covered only 16 patients and results need replication. Larger trials are necessary to confirm findings and determine if this treatment can become a standard option.
- Improving cancer survival rates generates significant economic value, with estimates suggesting returns between 500 and 1,000 percent on research investment. Policymakers continue evaluating funding for basic science to maximize long-term survival gains.
17 Articles
17 Articles
The ROI of Beating Cancer
Talk about pro-progress news—and a pro-progress lesson for government. New data from a cancer vaccine trial is a good reminder of what the half-century-old War on Cancer is actually worth. Patients who received a personalized mRNA vaccine for pancreatic cancer and mounted an immune response lived longer than those who did not, according to results presented at a major cancer research conference. Pancreatic cancer is notoriously lethal, killing m…
Pancreatic cancer patients continue to thrive after early trial of mRNA-based vaccine
Almost half of the participants in an early trial of an mRNA-based vaccine to fight pancreatic cancer were alive and well up to six years after treatment, according to new research. CNN’s Brianna Keilar speaks with Dr. Vinod Balachandran, director of the Olayan Center for Cancer Vaccines at Memorial Sloan Kettering Cancer Center, who led the study.
Krem2 News
mRNA vaccine hope for pancreatic cancer; fertility facts; smarter skin and hair care
Some promising things are happening in health news, including a possible personalized vaccine against pancreatic cancer. Hear what doctors are doing. (WKYC)
Coverage Details
Bias Distribution
- 82% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
